The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer.
BACKGROUND
Tetranectin (TN), a tetrameric, plasminogen-binding protein, was reduced in the plasma of patients with cancer and appears extracellularly in "stimulated" connective tissues, such as the proliferative, connective tissue response to carcinomas known as desmoplasia.


METHODS
Tissue samples from 37 patients with ovarian cancer were examined immunohistochemically for stromal and cellular TN. Plasma samples obtained before the primary surgery were quantitated for TN. The univariate log-rank test and the multivariate Cox proportional hazards regression model were used to analyze the prognostic function of the variables.


RESULTS
A significantly higher survival rate was found for patients with a low-stromal TN score and a high-plasma TN concentration, whereas the cellular TN score did not have any significance. A significant negative correlation was found between plasma TN and stromal TN (RS = -0.36; P = 0.03). Independent significant correlations were found between stromal immunoreactivity for TN and tumor grade (R = 0.67; P = 0.03) and between plasma TN and tumor stage (R = -0.29; P = 0.01).


CONCLUSIONS
This study gives great expectations to TN as a useful parameter for prognostic evaluation of patients with ovarian cancer. According to the correlations, stromal TN may partly originate from plasma and enhance proteolytic degradation in the interstitial tissue, a process necessary for the spread and growth of cancer. Because plasma TN measurements are only valid when taken preoperatively, it is of great value that stromal TN immunoreactivity of stored tumor tissue can be used as a prognostic factor for ovarian cancer.
Høgdall
C K
CK
Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, Denmark.
Christensen
L
L
Clemmensen
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D001798:Blood Proteins / Q000032:analysis* / Q000276:immunology; D005109:Extracellular Matrix / Q000737:chemistry; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D037181:Lectins, C-Type; D015993:Life Tables; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000097:blood / Q000737:chemistry* / Q000175:diagnosis / Q000401:mortality; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate
D014408:Biomarkers, Tumor; D001798:Blood Proteins; D037181:Lectins, C-Type; C048648:tetranectin